Drug intelligence / Profile preview

SA-083

Development stage: Preclinical
Lead developer: Double Bond Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

SA-083 is a drug candidate under development by Double Bond Pharma. It is a novel formulation of SA-033, designed to direct the chemotherapeutic agent doxorubicin specifically to the lungs for the treatment of lung cancer. The approach aims to enhance the delivery and concentration of doxorubicin in lung tissue, potentially improving efficacy against lung tumors while reducing systemic toxicity compared to conventional administration methods. This targeted delivery system leverages Double Bond Pharma's Belogal platform technology[2].

Targets

DNA

Beyond the preview

Go deeper on SA-083.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA-083.

Explore the full profile